| Document |
Document Title |
|
WO/2019/073987A1 |
Provided is a method for efficiently producing 2,5-bis (aminomethyl) tetrahydrofuran. This method for producing 2,5-bis (aminomethyl) tetrahydrofuran includes a step in which a hydrogen supply source is reacted with 2,5-bis (aminomethyl)...
|
|
WO/2019/074824A1 |
The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proli...
|
|
WO/2019/075084A1 |
Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-l...
|
|
WO/2019/071911A1 |
The present invention provides a 5A5B6C tricyclic spirolactone derivative. The 5A5B6C tricyclic spirolactone derivative described in the present invention has a chemical structure represented by general formula XI. The present invention ...
|
|
WO/2019/073388A1 |
The present disclosure relates to a new salt of escitalopram and its solid state forms, processes for the preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2019/069889A1 |
Provided are a compound having parasitic plant germination regulatory activity (especially parasitic plant germination induction activity), and a parasitic plant germination regulator in which said compound is used. A compound represente...
|
|
WO/2019/070123A1 |
The invention is directed to a process for the continuous preparation of a cycloadduct product from the reaction of a furanic with a dienophile, comprising heating a first liquid feed stream comprising the dienophile and a solvent in whi...
|
|
WO/2019/070236A1 |
The present invention is directed to a compound of Formula III or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula III wherein ...
|
|
WO/2019/068783A1 |
The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
|
|
WO/2019/068782A1 |
The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
|
|
WO/2019/070981A1 |
The present invention is directed to processes for producing isocyanates and isocyanate derivatives from epoxide and carbon monoxide reagents. In preferred embodiments, the processes include a step for providing carbonylation of an epoxi...
|
|
WO/2019/068583A1 |
The presently claimed invention is directed to a process for preparing D-glucaro-6,3-lactone monoamide from D-glucaro-6,3-lactone.
|
|
WO/2019/070807A1 |
Methods of treating a viral infection in a subject are provided. The methods include administering a therapeutically effective amount of a pharmaceutical composition comprising ginkgolic acid (GA) to the subject in need thereof, where th...
|
|
WO/2019/068834A1 |
The invention relates to a composition and a method for tanning, in particular for pretanning, hides and/or skins, the composition for tanning being anhydrous and containing an acetal of an aldehyde tanning agent and a non-combustible or...
|
|
WO/2019/063546A1 |
The invention relates to a process for converting a feedstock comprising at least one sugar into 5-hydroxymethylfurfural, wherein said feedstock is brought into contact with one or more inorganic dehydration catalysts and one or more chl...
|
|
WO/2019/067332A1 |
The present invention relates to methods of treating a cell proliferation disorder (e.g., cancer) comprising administering: (a) a compound having the Formula (I), wherein R1 or R2 are as herein defined, or a pharmaceutically acceptable s...
|
|
WO/2019/061299A1 |
Provided is a one-step amination reaction for producing an aminomethyl substituted heterocycloalkane, notably (tetrahydrofuran-2, 5-diyl) dimethanamine.
|
|
WO/2019/065928A1 |
The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of inflammatory diseases of the central nervous system, or a pharmacologically acceptable salt thereof. Provided is a compound represent...
|
|
WO/2019/063545A1 |
The invention relates to a novel process for converting a feedstock comprising at least one sugar into 5-hydroxymethylfurfural, wherein said feedstock is brought into contact with one or more organic dehydration catalysts and one or more...
|
|
WO/2019/066250A1 |
The present invention provides: a compound represented by chemical formula 1 or chemical formula A; an organic electronic element comprising a first electrode, a second electrode, and an organic layer between the first electrode and the ...
|
|
WO/2019/066242A1 |
Disclosed are: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode; and an electronic dev...
|
|
WO/2019/062561A1 |
Provided herein the synthesis methods of firocoxib and an intermediate thereof. The synthesis of the first intermediate is performed through methylation of p-bromopropiophenone or through Friedel-Crafts acylation of bromobenzene, avoidin...
|
|
WO/2019/063952A1 |
The invention relates to a new method for the synthesis of unsymmetrical tertiary amines using alcohol and an imine, and to new tertiary amines.
|
|
WO/2019/057969A1 |
The present invention relates to small molecule compounds and their use as agonists of farnesoid X receptor (FXR) and/or peroxisome proliferator activated receptor delta (PPARδ). The present invention also relates to the use of said com...
|
|
WO/2019/059515A1 |
The present invention relates to: a novel catalyst for preparing a transportation fuel precursor from a biomass-derived furan-based compound; and a method for preparing a polymer of a furan-based compound by using the same. The catalyst ...
|
|
WO/2019/059344A1 |
The present invention addresses the problem of providing a novel chemically activated water-soluble prodrug. The present invention provides a compound represented by formula (1), or a pharmacologically acceptable salt thereof (in the for...
|
|
WO/2019/056123A1 |
Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The can...
|
|
WO/2019/056120A1 |
The present application relates to sulfonamide containing compounds of Formulae (I) and (II) and compositions containing said compounds effective in the treatment of cell proliferative disorders, in particular cancer, and various methods...
|
|
WO/2019/052937A1 |
The invention relates to a process for separating furanic compounds from a feedstock additionally containing dimethoxysulfoxide (DMSO). These furanic compounds are in particular 5-hydroxymethylfurfural (5-HMF), 2,5-diformylfuran (DFF), 2...
|
|
WO/2019/049946A1 |
The present invention provides a photoelectric conversion element which has excellent photoelectric conversion efficiency even in cases where a photoelectric conversion film is a thin film. The present invention also provides a photosens...
|
|
WO/2019/046931A1 |
Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions invol...
|
|
WO/2019/048458A1 |
The present application relates to compounds of formulas (I) and (II), to methods for the production thereof, and to the use thereof in electronic devices.
|
|
WO/2019/050649A1 |
The present invention is directed to catalysts and processes for catalyzing two or more chemical reactions with a multifunctional catalyst in a reaction vessel. The processes include steps for introducing one or more reagents to a reacti...
|
|
WO/2019/048443A1 |
The present application relates to compounds of formula (I), to methods for the producing thereof, and to the use thereof in electronic devices.
|
|
WO/2018/139767A9 |
The present invention provides a novel amine-based compound and an organic light emitting device using the same.
|
|
WO/2019/042804A1 |
The invention relates to surfactants of general formula (I) in which R1 and R2 represent independently of one another represent H and S03 - X+ with the proviso that at least one of R1 and R2 is not H, n and m represent independently from...
|
|
WO/2019/043415A1 |
A process is disclosed for the hydrogenation of a compound comprising an α,β-unsaturated carbonyl group to form a compound comprising an allyl alcohol group, wherein the hydrogenation is carried out in the presence of a hydrogenation c...
|
|
WO/2018/017368A9 |
The inventive subject matter provides compounds, compositions and methods for lowering serum acid (sUA) for the treatment of gout, and having reduced liver toxicity, associated with CYP2C9 metabolic pathway.
|
|
WO/2019/041317A1 |
Provided is a method for preparing an important intermediate, ((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydro
furan-2-yl) methylbenzoate, of sofosbuvir.
|
|
WO/2019/043060A1 |
The present invention relates to binaphthyl compounds of the formula (I), which are suitable as monomers for preparing polycarbonate resins having beneficial optical properties and which can be used for producing optical lenses: Formula ...
|
|
WO/2019/042805A1 |
The invention relates to surfactants of general formula (I) in which R represents a linear or branched alkyl, alkenyl, alkylaryl or alkenylaryl group having 5 - 25 C atoms and X+ represents a charge-balancing cation. The surfactants can ...
|
|
WO/2019/043610A1 |
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...
|
|
WO/2019/044914A1 |
The present invention addresses the problem of providing a drug solution purification method with which it is possible to obtain a drug solution exhibiting excellent impairment suppression performance. The present invention also addresse...
|
|
WO/2019/043414A1 |
Process is disclosed for the hydrogenation of a compound comprising an α,β-unsaturated carbonyl group to form a compound comprising an allyl alcohol group, wherein the hydrogenation is carried out in the presence of a hydrogenation cat...
|
|
WO/2019/043300A1 |
According to an example aspect of the present invention, there is provided a synthesis method for producing furoic acid from a monoacid containing five carbons in the presence of pressure, heat,solvent and catalyst.
|
|
WO/2019/045528A1 |
The present invention provides a novel compound and an organic light emitting device using the same.
|
|
WO/2019/037860A1 |
Compounds of formula (I) wherein A, R, W, Q, L, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
|
|
WO/2019/040389A1 |
The present invention relates novel furan based amine cross-linkers with improved thermomechanical and water barrier properties. The novelty of this invention is the use of aromatic, and hydrophobic aliphatic aldehydes to bridge two furf...
|
|
WO/2019/040418A1 |
Compounds and methods for treating viral infections and reducing viral multiplication, including flaviviruses. Provided is a derivative of a compound or a pharmaceutical salt thereof, wherein the compound comprises a 3',4-didehydroribose.
|
|
WO/2019/040467A1 |
α-Cyanoacrylamide and α-cyanoacrylate compounds that allosterically inhibit Myeloid Cell Leukemia-1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease.
|
